These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 15117573)

  • 1. Comparison of liposome-encapsulated acyclovir with acyclovir ointment: ocular pharmacokinetics in rabbits.
    Chetoni P; Rossi S; Burgalassi S; Monti D; Mariotti S; Saettone MF
    J Ocul Pharmacol Ther; 2004 Apr; 20(2):169-77. PubMed ID: 15117573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acyclovir-containing liposomes for potential ocular delivery. Corneal penetration and absorption.
    Law SL; Huang KJ; Chiang CH
    J Control Release; 2000 Jan; 63(1-2):135-40. PubMed ID: 10640587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topical delivery of different acyclovir palmitate liposome formulations through rat skin in vitro.
    Liu H; Pan WS; Tang R; Luo SD
    Pharmazie; 2004 Mar; 59(3):203-6. PubMed ID: 15074594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ocular pharmacokinetics of acyclovir amino acid ester prodrugs in the anterior chamber: evaluation of their utility in treating ocular HSV infections.
    Katragadda S; Gunda S; Hariharan S; Mitra AK
    Int J Pharm; 2008 Jul; 359(1-2):15-24. PubMed ID: 18472234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonpolymeric nanoassemblies for ocular administration of acyclovir: pharmacokinetic evaluation in rabbits.
    Stella B; Arpicco S; Rocco F; Burgalassi S; Nicosia N; Tampucci S; Chetoni P; Cattel L
    Eur J Pharm Biopharm; 2012 Jan; 80(1):39-45. PubMed ID: 22008147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intraocular penetration of topically administered acyclovir.
    Kitagawa K; Fukuda M; Sasaki K
    Lens Eye Toxic Res; 1989; 6(1-2):365-73. PubMed ID: 2488028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effects of honey to acyclovir in the rabbit eye transport kinetics].
    He Q; Wang S; Zhang X; Zhang J; Jiang Y; Xu J
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(19):2723-6. PubMed ID: 22242438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved permeability of acyclovir: optimization of mucoadhesive liposomes using the phospholipid vesicle-based permeation assay.
    Naderkhani E; Erber A; Škalko-Basnet N; Flaten GE
    J Pharm Sci; 2014 Feb; 103(2):661-8. PubMed ID: 24395733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo ocular pharmacokinetics of acyclovir dipeptide ester prodrugs by microdialysis in rabbits.
    Anand BS; Katragadda S; Gunda S; Mitra AK
    Mol Pharm; 2006; 3(4):431-40. PubMed ID: 16889437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Failure of topical acyclovir in ointment to penetrate human skin.
    Freeman DJ; Sheth NV; Spruance SL
    Antimicrob Agents Chemother; 1986 May; 29(5):730-2. PubMed ID: 3729337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of correlation between skin target site free drug concentration and the in vivo topical antiviral efficacy in hairless mice for (E)-5-(2-bromovinyl)-2'-deoxyuridine and acyclovir formulations.
    Afouna MI; Mehta SC; Ghanem AH; Higuchi WI; Kern ER; De Clercq E; El-Shattawy HH
    J Pharm Sci; 1998 Aug; 87(8):917-21. PubMed ID: 9687333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo quantification of acyclovir exposure in the dermis following iontophoresis of semisolid formulations.
    Shukla C; Friden P; Juluru R; Stagni G
    J Pharm Sci; 2009 Mar; 98(3):917-25. PubMed ID: 18623192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of acyclovir in rabbit skin after i.v.-bolus, ointment, and iontophoretic administrations.
    Stagni G; Ali ME; Weng D
    Int J Pharm; 2004 Apr; 274(1-2):201-11. PubMed ID: 15072796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liposomes as a potential ocular delivery system of distamycin A.
    Chetoni P; Monti D; Tampucci S; Matteoli B; Ceccherini-Nelli L; Subissi A; Burgalassi S
    Int J Pharm; 2015 Aug; 492(1-2):120-6. PubMed ID: 26183332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of drug loading and type of ointment base on the in vitro performance of acyclovir ophthalmic ointment.
    Al-Ghabeish M; Xu X; Krishnaiah YS; Rahman Z; Yang Y; Khan MA
    Int J Pharm; 2015 Nov; 495(2):783-91. PubMed ID: 26343911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical toxicology studies with acyclovir: ophthalmic and cutaneous tests.
    Tucker WE; Johnston RE; Macklin AW; Szot RJ; Elion GB; de Miranda P; Szczech GM
    Fundam Appl Toxicol; 1983; 3(6):569-72. PubMed ID: 6662298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioavailability of two oral suspension and two oral tablet formulations of acyclovir 400 mg: two single-dose, open-label, randomized, two-period crossover comparisons in healthy Mexican adult subjects.
    Palma-Aguirre JA; Absalón-Reyes JA; Novoa-Heckel G; de Lago A; Oliva I; Rodríguez Z; González-de la Parra M; Burke-Fraga V; Namur S
    Clin Ther; 2007 Jun; 29(6):1146-52. PubMed ID: 17692728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical iontophoresis of valaciclovir hydrochloride improves cutaneous aciclovir delivery.
    Abla N; Naik A; Guy RH; Kalia YN
    Pharm Res; 2006 Aug; 23(8):1842-9. PubMed ID: 16850271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of topically applied 5-ethyl-2'-deoxyuridine and acyclovir in the treatment of cutaneous herpes simplex virus infection in guinea pigs.
    Spruance SL; Freeman DJ; Sheth NV
    Antimicrob Agents Chemother; 1985 Jul; 28(1):103-6. PubMed ID: 4037770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formulation of acyclovir-loaded solid lipid nanoparticles: 2. Brain targeting and pharmacokinetic study.
    El-Gizawy SA; El-Maghraby GM; Hedaya AA
    Pharm Dev Technol; 2019 Dec; 24(10):1299-1307. PubMed ID: 31507245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.